These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34431262)

  • 41. Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients?
    Sharma DN; Welsh J; Kumar R
    J Cancer Res Ther; 2021; 17(6):1294-1296. PubMed ID: 34916356
    [No Abstract]   [Full Text] [Related]  

  • 42. Mucormycosis: time to address this deadly fungal infection.
    Stone N; Gupta N; Schwartz I
    Lancet Microbe; 2021 Aug; 2(8):e343-e344. PubMed ID: 35544192
    [No Abstract]   [Full Text] [Related]  

  • 43. Concurrent plexiform ameloblastoma and COVID-19-associated mucormycosis of the maxilla.
    Ingle Y; Sarode SC; Sarode G; Ingle M; Ingle S
    Oral Oncol; 2022 Feb; 125():105712. PubMed ID: 35016140
    [No Abstract]   [Full Text] [Related]  

  • 44. Post-COVID-19 mucormycosis complication: a black fungal infection.
    Uttamchandani SR; Phansopkar PA
    Pan Afr Med J; 2022; 43():205. PubMed ID: 36942133
    [No Abstract]   [Full Text] [Related]  

  • 45. COVID-19-associated mucormycosis-elucidating the etiology of this emerging entity.
    Sakthivel P; Ish P
    QJM; 2022 Jun; 115(6):421. PubMed ID: 34264350
    [No Abstract]   [Full Text] [Related]  

  • 46. Mucormycosis, conflicts and COVID-19: A deadly recipe for the fragile health system of Afghanistan.
    Essar MY; Khan H; Babar MS; Hasan MM; Rackimuthu S; Dos Santos Costa AC; Ahmad S; Nemat A
    Int J Health Plann Manage; 2022 Jan; 37(1):543-546. PubMed ID: 34333804
    [No Abstract]   [Full Text] [Related]  

  • 47. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
    Sharma S; Grover M; Bhargava S; Samdani S; Kataria T
    J Laryngol Otol; 2021 May; 135(5):442-447. PubMed ID: 33827722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-COVID-19 Isolated Renal Mucormycosis Coincidence vs Association.
    Shastri M; Rathod VM; Raval DM
    J Assoc Physicians India; 2022 Nov; 70(11):11-12. PubMed ID: 37355956
    [No Abstract]   [Full Text] [Related]  

  • 49. Nasal Microbiota Imbalance as a Contributory Link in the Emergence of COVID-19 Associated Mucormycosis.
    Singh R; Kumari A
    ACS Infect Dis; 2021 Aug; 7(8):2211-2213. PubMed ID: 34328718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The rise of mucormycosis in Covid-19 patients in India.
    Bhatia M
    Expert Rev Anti Infect Ther; 2022 Feb; 20(2):137-138. PubMed ID: 34304680
    [No Abstract]   [Full Text] [Related]  

  • 51. 'Black turbinates' in COVID-associated sino-nasal mucormycosis.
    Ghonge NP; Nagpal K; Malla S
    QJM; 2022 Dec; 115(12):851-852. PubMed ID: 35959989
    [No Abstract]   [Full Text] [Related]  

  • 52. COVID-19 associated with concomitant mucormycosis and aspergillosis.
    Lai CC; Wu CJ; Lee YC; Liu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):353-354. PubMed ID: 34563471
    [No Abstract]   [Full Text] [Related]  

  • 53. Rare case of gastrointestinal mucormycosis with colonic perforation in an immunocompetent patient with COVID-19.
    Singh RP; Gupta N; Kaur T; Gupta A
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34215642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucor in a Viral Land: A Tale of Two Pathogens.
    Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
    Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absence of Case of Mucormycosis (March 2020-May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit.
    Mulakavalupil B; Vaity C; Joshi S; Misra A; Pandit RA
    Diabetes Metab Syndr; 2021; 15(4):102169. PubMed ID: 34198110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Covid-19-associated mucormycosis in patients with renal failure.
    Patil A; Rao N; Kumar K; Modi T; Gandhi C; Deb S; Bose S; Saxena N; Katyal A; Thakare S; Pajai AE; Bajpai D; Jamale TE
    Natl Med J India; 2022; 35(3):187-189. PubMed ID: 36461873
    [No Abstract]   [Full Text] [Related]  

  • 57. Determining the optimal strategy for reopening schools, the impact of test and trace interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK: a modelling study.
    Panovska-Griffiths J; Kerr CC; Stuart RM; Mistry D; Klein DJ; Viner RM; Bonell C
    Lancet Child Adolesc Health; 2020 Nov; 4(11):817-827. PubMed ID: 32758453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phylogenetic analysis of SARS-CoV-2 lineage development across the first and second waves in Eastern Germany in 2020: insights into the cause of the second wave.
    Yi B; Poetsch AR; Stadtmüller M; Rost F; Winkler S; Dalpke AH
    Epidemiol Infect; 2021 Jul; 149():e177. PubMed ID: 34325753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology and clinical features of emergency department patients with suspected COVID-19: Insights from Australia's 'second wave' (COVED-4).
    O'Reilly GM; Mitchell RD; Mitra B; Akhlaghi H; Tran V; Furyk JS; Buntine P; Wong A; Gangathimmaiah V; Knott J; Raos M; Chatterton E; Sevior C; Parker S; Baker S; Loughman A; Lowry N; Freeman D; Sri-Ganeshan M; Chapman N; Siu S; Noonan MP; Smit V; Cameron PA;
    Emerg Med Australas; 2021 Apr; 33(2):331-342. PubMed ID: 33315310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea.
    Ryu S; Ali ST; Noh E; Kim D; Lau EHY; Cowling BJ
    BMC Infect Dis; 2021 May; 21(1):485. PubMed ID: 34039296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.